Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the 2024 Cantor Fitzgerald Global Healthcare Conference. The company's management will engage in a fireside chat on September 18, 2024, at 8:00 a.m. ET in New York City.
Investors and the public can access a live webcast of the chat through the 'Investors' section on Artivabio.com. A replay will be available for 90 days after the event. Additionally, Artiva's management team will be available for in-person investor meetings during the conference.
Artiva Biotherapeutics (Nasdaq: ARTV), una compagnia biotecnologica in fase clinica focalizzata nello sviluppo di terapie cellulari per malattie autoimmuni e tumori, ha annunciato la sua partecipazione alla Conferenza Sanitaria Globale Cantor Fitzgerald 2024. Il management dell’azienda parteciperà a un fireside chat il 18 settembre 2024, alle 8:00 a.m. ET a New York City.
Investitori e pubblico possono accedere a un webcast dal vivo della conversazione attraverso la sezione 'Investitori' su Artivabio.com. Una registrazione sarà disponibile per 90 giorni dopo l'evento. Inoltre, il team di gestione di Artiva sarà disponibile per incontri di persona con gli investitori durante la conferenza.
Artiva Biotherapeutics (Nasdaq: ARTV), una empresa biotecnológica en etapa clínica enfocada en el desarrollo de terapias celulares para enfermedades autoinmunes y cánceres, ha anunciado su participación en la Conferencia Global de Salud Cantor Fitzgerald 2024. La administración de la empresa participará en una charla informal el 18 de septiembre de 2024, a las 8:00 a.m. ET en Nueva York.
Los inversores y el público pueden acceder a una transmisión en vivo de la charla a través de la sección 'Inversores' en Artivabio.com. La repetición estará disponible durante 90 días después del evento. Además, el equipo de gestión de Artiva estará disponible para reuniones presenciales con inversores durante la conferencia.
Artiva Biotherapeutics (Nasdaq: ARTV)는 자가 면역 질환 및 암 치료를 위한 세포 치료제 개발에 중점을 둔 임상 단계의 생명공학 회사로, 2024 캔터 피츠제럴드 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사의 경영진은 2024년 9월 18일 오전 8시(ET)에 뉴욕시에서 진행되는 파이어사이드 차트에 참여할 예정입니다.
투자자와 대중은 Artivabio.com의 '투자자' 섹션을 통해 실시간 웹캐스트를 이용할 수 있습니다. 행사 후 90일 동안 다시 볼 수 있습니다. 또한 Artiva의 경영진은 컨퍼런스 기간 동안 대면 투자자 회의를 위해 참석할 예정입니다.
Artiva Biotherapeutics (Nasdaq: ARTV), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies cellulaires pour les maladies auto-immunes et les cancers, a annoncé sa participation à la Conférence Mondiale sur la Santé Cantor Fitzgerald 2024. La direction de l'entreprise participera à une discussion informelle le 18 septembre 2024, à 8h00 ET à New York.
Les investisseurs et le public peuvent accéder à un webinaire en direct de la discussion via la section 'Investisseurs' sur Artivabio.com. Un replay sera disponible pendant 90 jours après l'événement. De plus, l'équipe de direction d'Artiva sera disponible pour des réunions en personne avec les investisseurs durant la conférence.
Artiva Biotherapeutics (Nasdaq: ARTV), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von zellbasierten Therapien für Autoimmunerkrankungen und Krebs konzentriert, hat seine Teilnahme an der 2024 Cantor Fitzgerald Global Healthcare Conference angekündigt. Das Management des Unternehmens wird am 18. September 2024 um 8:00 Uhr ET in New York City an einem Fireside-Chat teilnehmen.
Investoren und die Öffentlichkeit können über den 'Investoren'-Bereich auf Artivabio.com einen Live-Webcast des Chats abrufen. Eine Wiederholung wird 90 Tage nach der Veranstaltung verfügbar sein. Darüber hinaus wird das Management-Team von Artiva während der Konferenz für persönliche Investorengespräche zur Verfügung stehen.
- None.
- None.
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, 2024, at 8:00 a.m. ET / 5:00 a.m. PT, in New York City, New York.
Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference.
Investors and the general public are invited to listen to a live webcast of the fireside chat through the "Investors" section on Artivabio.com. A webcast replay will be made available following the event for 90 days.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit https://www.artivabio.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding upcoming events or Artiva Biotherapeutics, Inc.’s (the “Company”) participation at such events. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091
FAQ
When is Artiva Biotherapeutics (ARTV) participating in the Cantor Fitzgerald Global Healthcare Conference?
What time is Artiva Biotherapeutics' (ARTV) fireside chat at the 2024 Cantor Fitzgerald conference?
Where can investors watch the live webcast of Artiva Biotherapeutics' (ARTV) fireside chat?
How long will the replay of Artiva Biotherapeutics' (ARTV) fireside chat be available?
What types of therapies is Artiva Biotherapeutics (ARTV) developing?
